Research ArticleArticle
A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis
Mark C. Genovese, Stanley B. Cohen, David Wofsy, Michael E. Weinblatt, Gary S. Firestein, Ernest Brahn, Vibeke Strand, Daniel G. Baker and Sandra E. Tong
The Journal of Rheumatology February 2011, jrheum.100602; DOI: https://doi.org/10.3899/jrheum.100602
Mark C. Genovese
Stanley B. Cohen
David Wofsy
Michael E. Weinblatt
Gary S. Firestein
Ernest Brahn
Vibeke Strand
Daniel G. Baker
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis
Mark C. Genovese, Stanley B. Cohen, David Wofsy, Michael E. Weinblatt, Gary S. Firestein, Ernest Brahn, Vibeke Strand, Daniel G. Baker, Sandra E. Tong
The Journal of Rheumatology Feb 2011, jrheum.100602; DOI: 10.3899/jrheum.100602
A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis
Mark C. Genovese, Stanley B. Cohen, David Wofsy, Michael E. Weinblatt, Gary S. Firestein, Ernest Brahn, Vibeke Strand, Daniel G. Baker, Sandra E. Tong
The Journal of Rheumatology Feb 2011, jrheum.100602; DOI: 10.3899/jrheum.100602